Morphic is a biopharmaceutical company. Co. is applying its proprietary insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with various approved injectable blockbuster drugs for the treatment of chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Co. is developing its pipeline, including its main product candidate, MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease. Co. has also developed selective oral avß6-specific integrin inhibitors including MORF-720 and MORF-627. The MORF average annual return since 2019 is shown above.
The Average Annual Return on the MORF average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MORF average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MORF average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|